Home
About Us
Subject
Browse
0
Sign In
177Lu-DOTATATE
Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
177
Lu-DOTATATE: A Case Report
Article
Year: 2021
Pages: 1
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
Article
Year: 2021
Pages: 9
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials
Article
Year: 2021
Pages: 1
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
Article
Year: 2021
Pages: 1
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with
177
Lu-DOTATATE
Article
Year: 2021
Pages: 10
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
New Developments in the Treatment of Neuroendocrine Tumours – RADIANT-4, NETTER-1 and Telotristat Etiprate
Article
Year: 2016
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
Imaging DNA Damage Repair In Vivo After
177
Lu-DOTATATE Therapy
Article
Pages: 8
Share
Facebook
Twitter
Linkedin
Whatsapp
More Info
Load More
More Info